Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, ASPIRIN AND CAFFEINE vs INH
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
FDA-approved: Temporary relief of minor aches and pains (headache, muscle ache, toothache, backache, menstrual cramps), reduction of fever.,Off-label: None commonly accepted.
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
Acetaminophen: 2-4 hours (prolonged in liver disease); aspirin: 15-20 minutes (active metabolite salicylate: 2-3 hours at low doses, prolonged to 15-30 hours at high doses); caffeine: 3-6 hours (prolonged in pregnancy, liver disease).
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1), and minor CYP2E1 (toxic metabolite NAPQI); Aspirin: hydrolyzed to salicylate, further metabolized by conjugation (glycine, glucuronic acid) and oxidation; Caffeine: hepatic via CYP1A2 (major), CYP2E1, CYP3A4, N-acetyltransferase.
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Acetaminophen: renal elimination of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%, unchanged 2%); aspirin: renal elimination of salicylate and metabolites (75% salicyluric acid, 10% glucuronides, 10% salicylate); caffeine: renal elimination of metabolites (paraxanthine, theobromine, theophylline; <3% unchanged). Total: >95% renal.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
Acetaminophen: 10-25% (albumin); aspirin: 80-90% (albumin, decreased at high doses); caffeine: 35% (albumin).
0-10% (low binding; primarily albumin).
Acetaminophen: 0.9-1.0 L/kg; aspirin: 0.15-0.2 L/kg (low); caffeine: 0.6-0.8 L/kg. Reflects distribution into total body water.
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Acetaminophen: oral 85-98%; aspirin: oral 50-80% (due to first-pass hydrolysis); caffeine: oral ~100%.
Oral: ~90%. Intramuscular: ~100%.
Contraindicated in severe renal impairment (Cr Cl <10 m L/min). For Cr Cl 10-50 m L/min: avoid aspirin component; consider alternative therapy. For Cr Cl >50 m L/min: no adjustment needed for acetaminophen; aspirin may require dose reduction or monitoring.
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
Child-Pugh A: caution with acetaminophen (max 2 g/day) and avoid caffeine if severe. Child-Pugh B: avoid aspirin; reduce acetaminophen dose (max 2 g/day) and limit caffeine. Child-Pugh C: contraindicated due to aspirin and acetaminophen risk.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Not recommended for children <12 years due to aspirin risk of Reye's syndrome. For adolescents ≥12 years: same as adult dosing: 1-2 tablets every 4-6 hours, max 8 tablets/24 hours.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
Caution due to increased sensitivity to aspirin (GI bleeding, renal impairment) and caffeine (insomnia, tachycardia). Start at low end of dosing: 1 tablet every 6 hours; monitor renal function and avoid long-term use.
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
Reye syndrome warning: Aspirin should not be used in children or teenagers with viral illnesses due to risk of Reye syndrome.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
Hepatotoxicity (acetaminophen overdose), gastrointestinal bleeding (aspirin), Reye syndrome (aspirin in children with viral illness), cardiovascular risk (aspirin may increase bleeding), caffeine-related CNS stimulation, risk of dependence.
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Hypersensitivity to any component; active peptic ulcer disease; bleeding disorders; severe hepatic impairment; children/adolescents with viral illness (Reye syndrome); third trimester of pregnancy (aspirin); concurrent use of other salicylates or NSAIDs; severe renal impairment.
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Alcohol increases risk of hepatotoxicity with acetaminophen and GI bleeding with aspirin. Caffeine-containing foods or beverages should be limited to avoid excessive caffeine intake. High-tyramine foods (e.g., aged cheeses, cured meats) may potentiate caffeine effects; no significant interaction documented.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible association with gastroschisis. Second trimester: Aspirin may increase risk of intracranial hemorrhage; acetaminophen and caffeine generally not linked to major malformations. Third trimester: Aspirin use is contraindicated due to risk of premature ductus arteriosus closure and oligohydramnios; high-dose acetaminophen may cause oligohydramnios; caffeine metabolism slows, but moderate intake appears safe; chronic high-dose caffeine may be associated with low birth weight.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
Acetaminophen: M/P ratio approximately 0.9; small amounts excreted; considered safe. Aspirin: M/P ratio variable, typically 0.12-0.42; avoid high doses due to risk of Reye's syndrome; single doses unlikely harmful. Caffeine: M/P ratio approximately 0.5-1.0; moderate intake (≤300 mg/day) considered safe; excessive intake may cause irritability in infant.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
Acetaminophen: No dose adjustment needed; standard dosing (650-1000 mg every 4-6 hours, max 3000 mg/day). Aspirin: Avoid doses >81 mg/day in third trimester; use lowest effective dose. Caffeine: Metabolism prolonged; limit to ≤200 mg/day (approximately 2 cups coffee).
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Acetaminophen, aspirin, and caffeine combination is used for mild to moderate pain and fever reduction. Aspirin component provides anti-inflammatory effects; caution in patients with bleeding disorders or those on anticoagulants due to increased bleeding risk. Acetaminophen hepatotoxicity risk with doses >4g/day or in liver disease. Caffeine may cause insomnia, tremor, or palpitations; avoid in patients with anxiety disorders. Reye syndrome risk with aspirin use in children with viral illnesses. Monitor renal function in elderly or dehydrated patients.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
Do not exceed recommended dose; acetaminophen overdose can cause liver damage.,Avoid alcohol while taking this medication.,Do not use in children or teenagers with viral illnesses due to Reye syndrome risk.,May cause stomach upset; take with food or milk.,Limit caffeine intake from other sources when using this medication.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
"Triamterene, a potassium-sparing diuretic, can inhibit the hepatic metabolism of caffeine by competing for cytochrome P450 (CYP) 1A2, the primary enzyme responsible for caffeine clearance. This leads to increased plasma caffeine concentrations and prolonged caffeine half-life, potentially causing caffeine toxicity manifesting as nervousness, insomnia, tachycardia, and diuresis enhancement. Patients may experience exaggerated stimulant effects and increased risk of cardiac arrhythmias when combining these agents."
"Caffeine inhibits the metabolism of sulfadiazine by competitively antagonizing cytochrome P450 (CYP) enzymes, particularly CYP1A2, leading to increased plasma concentrations of sulfadiazine. This elevates the risk of dose-dependent adverse effects, including crystalluria, nephrotoxicity, and hypersensitivity reactions. The interaction may also reduce the therapeutic efficacy of sulfadiazine due to altered pharmacokinetics."
"Caffeine inhibits the cytochrome P450 enzyme CYP2C9, which is primarily responsible for the metabolism of losartan to its active metabolite E-3174. This inhibition can lead to increased plasma concentrations of losartan and decreased formation of the active metabolite, potentially reducing losartan's antihypertensive efficacy. The clinical outcome may be suboptimal blood pressure control in patients consuming high amounts of caffeine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, ASPIRIN AND CAFFEINE vs INH, answered by our medical review team.
ACETAMINOPHEN, ASPIRIN AND CAFFEINE is a NSAID / Antiplatelet that works by Acetaminophen: weak COX-1/2 inhibitor, analgesic and antipyretic through central action; Aspirin: irreversible COX-1/2 inhibitor, anti-inflammatory, analgesic, antipyretic, antiplatelet; Caffeine: adenosine receptor antagonist, CNS stimulant, enhances analgesic effect.. INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, ASPIRIN AND CAFFEINE and INH depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, ASPIRIN AND CAFFEINE is: 1-2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine per tablet) orally every 4-6 hours as needed for pain or fever; maximum 8 tablets per 24 hours.. The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, ASPIRIN AND CAFFEINE and INH in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, ASPIRIN AND CAFFEINE is classified as Category D/X. First trimester: Aspirin is associated with increased risk of neural tube defects and cardiac malformations; acetaminophen is considered low risk but some studies suggest possible . INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.